 SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Cortexyme, Inc. NASDAQ: CRTX, a clinical-stage biopharmaceutical company focused on Alzheimers and other degenerative diseases, received a letter from the U.S. Food and Drug Administration FDA stating that a partial clinical hold has been placed on atuzaginstat COR388 impacting the open-label extension OLE phase of the companys ongoing Phase 23 study, the GAIN Trial. Under the hold, no new participants will be enrolled in the OLE and curr 